Treatment-Resistant Depression: What to Do Next

If you have tried two or more antidepressants at adequate doses for adequate durations and still do not feel better, you have not failed treatment. The current treatment plan has not yet matched your clinical picture. That distinction matters enormously, because it shifts the question from why isn’t this working on me? to what does the evidence say we should try next? Treatment-resistant depression is a recognized clinical condition with a structured, evidence-based pathway forward — and this post walks through exactly that pathway with the specificity you deserve.

What ‘Treatment-Resistant’ Actually Means Clinically

The term gets used loosely, which creates unnecessary confusion. Clinically, treatment-resistant depression (TRD) is generally defined as a major depressive episode that has not responded adequately to at least two different antidepressant trials, each conducted at a therapeutic dose for a sufficient duration — typically six to eight weeks at minimum.

That definition matters for a few reasons. First, it sets a threshold. If you tried a medication for two weeks at a low dose before stopping due to side effects, that may not meet the clinical bar for a failed adequate trial. Second, it clarifies that TRD is not a single diagnosis but a staging concept. Researchers and clinicians often use staging models — such as the Thase-Rush model — to describe how many adequate trials have failed and at what level of intervention the patient currently sits.

According to the National Institute of Mental Health, depression is one of the most common mental disorders in the United States, and a meaningful portion of people with major depression do not achieve full remission with initial treatment. That is not an outlier outcome. It is a known clinical reality that has driven decades of research into what to do next.

What TRD Is Not

It is worth naming a few things explicitly. Treatment-resistant depression is not the same as untreatable depression. It is also not evidence that you are somehow more difficult or more broken than other patients. And it is not a reason to stop trying.

What it is: a signal that the diagnostic and treatment picture needs a more careful look. Sometimes a missed diagnosis is part of the picture — for example, a bipolar spectrum condition, an undiagnosed attention deficit disorder, or a thyroid abnormality driving depressive symptoms. A structured psychiatric evaluation for refractory depression exists precisely to catch what earlier evaluations may have missed.

Why Standard Antidepressants Stop Working for Some Patients

This is a question worth answering directly, because many patients internalize the failure of a medication as something personal. It is not. There are several well-understood clinical reasons why depression does not respond to antidepressants for some individuals.

Biological Variability in Drug Metabolism

Pharmacogenomic research has established that individuals metabolize psychiatric medications differently based on genetic variation in liver enzymes — particularly the CYP450 enzyme family. A medication that reaches a therapeutic plasma level in one patient may be metabolized too rapidly in another, resulting in subtherapeutic exposure even at a standard dose. Some patients are rapid metabolizers of SSRIs and SNRIs. Others are poor metabolizers and may experience more side effects at standard doses. Neither scenario means the medication class is the wrong choice — it means the dose or the specific agent may need adjustment.

Diagnostic Complexity

Depression is not a monolithic condition. What presents as unipolar major depression may actually represent a bipolar II pattern, a trauma-related mood disturbance, an anxiety-primary picture with secondary depression, or a depression comorbid with ADHD — a combination that, when the ADHD goes untreated, can significantly undermine antidepressant response. Diagnostic precision at the front end of treatment matters enormously for outcomes.

Neurobiological Factors Beyond Serotonin

Standard antidepressants — SSRIs, SNRIs, and older agents like TCAs and MAOIs — primarily act on monoamine systems: serotonin, norepinephrine, and dopamine. But depression involves multiple neurobiological pathways, including glutamate signaling, neuroinflammation, and HPA axis dysregulation. For a subset of patients whose depression is driven more heavily by these pathways, monoamine-targeted medications may simply not be the most effective mechanism of action. This is one of the reasons why newer mechanisms of action — including NMDA receptor modulation — have shown promise in patients whose depression was not responding to standard approaches.

Evidence-Based Next Steps: Augmentation and Combination Strategies

Before escalating to advanced interventional options, there is a structured set of augmentation strategies for depression that are well-supported by clinical evidence. These are the steps most psychiatric providers will consider after two failed antidepressant trials.

Augmentation With Atypical Antipsychotics

Several second-generation antipsychotics have FDA approval specifically as adjunctive treatments for major depression when added to an antidepressant. Aripiprazole, quetiapine, and brexpiprazole all fall into this category. The mechanism differs from traditional antidepressants — these agents act on dopamine and serotonin receptors in ways that can enhance antidepressant effect when added to an existing regimen. The evidence base for this approach is substantial, and it is often a logical first escalation step after two failed monotherapy trials.

Lithium Augmentation

Lithium has one of the longest evidence trails of any augmentation strategy in psychiatry. Adding low-dose lithium to an antidepressant has been studied for decades and continues to be a recommended option in clinical guidelines. It requires monitoring of blood levels and kidney function, which adds a layer of clinical management — but for patients who have failed multiple trials, it remains a meaningful option.

Thyroid Hormone Augmentation

The addition of triiodothyronine (T3) to an antidepressant is an older but still relevant strategy. Even in patients without frank hypothyroidism, thyroid augmentation has shown benefit in some studies. This is also a reason why a thorough evaluation should include thyroid function testing — it is a correctable contributor to antidepressant non-response that is sometimes overlooked.

Switching Antidepressant Class

Sometimes the right move is not augmentation but a clean switch to a different antidepressant class or mechanism. For example, a patient who has failed two SSRIs may respond to a norepinephrine-dopamine reuptake inhibitor like bupropion, or a serotonin modulator like vortioxetine, which acts on multiple receptor subtypes beyond simple reuptake inhibition. The clinical rationale here is that different mechanisms may be more relevant to an individual’s specific neurobiological profile.

Psychotherapy as a Clinical Intervention

This is worth stating clearly: psychotherapy — specifically cognitive behavioral therapy (CBT) and behavioral activation — is not a soft supplement to medication. It is a clinically active intervention with its own evidence base, and the combination of medication with structured psychotherapy consistently outperforms either treatment alone in patients with moderate to severe depression. If your current treatment has not included structured psychotherapy, that is a meaningful gap worth addressing.

Advanced Interventional Options: Esketamine, TMS, and Beyond

When augmentation strategies have been tried and found insufficient, the clinical landscape includes several advanced interventional options that have changed the treatment calculus for TRD clinical options significantly over the past decade.

Esketamine (Spravato) for Depression

In 2019, the FDA approved esketamine nasal spray — marketed as Spravato — specifically for treatment-resistant depression. This was a landmark approval because it introduced a new mechanism of action: NMDA receptor antagonism via the glutamate pathway. Unlike traditional antidepressants that can take four to six weeks to show effect, esketamine can produce antidepressant effects within hours to days in some patients.

According to the FDA’s approval announcement, esketamine is administered as a nasal spray in a certified healthcare setting under direct medical supervision, with the patient monitored for at least two hours after each session. It is not a medication taken at home independently. The clinical trial data supporting approval, including research published in the New England Journal of Medicine, demonstrated statistically significant benefit for patients with TRD compared to placebo augmentation.

Important clinical context: Esketamine is not a first-line treatment and is not appropriate for everyone. It carries specific contraindications — including a history of psychosis, certain cardiovascular conditions, and active substance use disorders — and is administered only in certified outpatient settings. The decision to pursue esketamine for depression should follow a careful evaluation of the patient’s full clinical picture.

Transcranial Magnetic Stimulation (TMS)

TMS is a non-invasive neurostimulation treatment that uses magnetic pulses to stimulate specific regions of the prefrontal cortex involved in mood regulation. It is FDA-cleared for major depression and has a well-established evidence base across multiple years of clinical use. Unlike electroconvulsive therapy (ECT), TMS does not require anesthesia and does not produce the cognitive side effects associated with ECT.

Standard TMS protocols involve daily outpatient sessions across several weeks. Newer accelerated protocols, including theta burst stimulation, condense that treatment window significantly. TMS is a particularly relevant option for patients who cannot tolerate pharmacologic augmentation strategies or who prefer a non-medication pathway. The practice’s own clinical background includes direct experience with TMS-focused treatment — relevant context for any patient considering this option.

Electroconvulsive Therapy (ECT)

ECT carries significant stigma that, frankly, does not reflect its current clinical profile. Modern ECT is conducted under brief anesthesia, is highly effective for severe or psychotic depression, and remains one of the most effective acute interventions in psychiatry for cases where rapid response is needed — including active suicidal crisis or severe functional impairment. It is typically considered after other interventional options have been tried, or when the severity of presentation demands faster action.

Emerging Options: Oral Ketamine and Psychedelic-Assisted Therapy

Research into oral ketamine formulations and psychedelic-assisted therapies — particularly psilocybin and MDMA for depression and trauma-related conditions — is advancing, though most of these remain investigational in standard clinical settings. Patients interested in these options should discuss current availability and legal context with their psychiatric provider directly. Clinical trials remain an option worth exploring for patients who meet eligibility criteria.

The Role of a Comprehensive Psychiatric Evaluation in Moving Forward

This is the step that is most commonly skipped — or done inadequately — in the journey of a patient with treatment-resistant depression. A genuine re-evaluation at the point of treatment failure is not the same as a brief medication check appointment. It is a structured clinical process.

According to the American Psychiatric Association, treatment planning for depression should be individualized and evidence-based, accounting for the full clinical picture including comorbidities, functional impairment, psychosocial factors, and prior treatment history.

A comprehensive psychiatric evaluation for refractory depression should include:

• Complete medication history — every trial, dose, duration, and reason for discontinuation. This establishes what has actually been tried versus what qualifies as an adequate trial.
• Diagnostic re-examination — explicitly revisiting whether the original diagnosis is correct or complete. This includes screening for bipolar spectrum features, trauma history, anxiety disorders, and neurodevelopmental conditions like ADHD.
• Medical workup review — confirming thyroid function, ruling out anemia, vitamin D deficiency, and other medical contributors to depressive symptoms.
• Pharmacogenomic testing consideration — in select cases, genetic testing can provide useful information about how a patient metabolizes specific psychiatric medications, helping guide selection and dosing decisions.
• Functional assessment — not just symptom checklist scores, but a clear picture of how depression is affecting work performance, relationships, sleep, and daily function. Treatment goals should be tied to real-world outcomes, not just symptom reduction scores.
• Psychosocial and lifestyle factors — chronic stress, inadequate sleep, substance use, and social isolation can all significantly undermine treatment response and are worth addressing systematically.

It is also worth noting that ADHD and depression co-occur at clinically significant rates. Untreated ADHD creates persistent functional impairment that can look like, or actively worsen, depression — and antidepressants alone will not resolve ADHD-driven dysfunction. If you are in California and have not had a thorough ADHD evaluation as part of your workup, that is a gap worth closing. You can learn more about what a structured evaluation looks like through D&Y’s Adult ADHD Evaluation service in San Francisco or the Adult ADHD Evaluation in San Gabriel — both designed for working adults who need clarity, not guesswork.

How to Have a Productive Conversation With Your Prescriber

One of the consistent pain points for patients with treatment-resistant depression is the experience of leaving appointments without clarity — not knowing why a new medication was chosen, what the plan is if it does not work, or what the threshold is for escalating to a different approach. You deserve answers to those questions. Here is how to ask for them.

Before the Appointment

• Write out every medication you have tried: name, approximate dose, duration, reason for stopping, and what effect (if any) it had. This is your treatment history, and your provider needs it to make good decisions.
• Be specific about your current functional state. Not just that you feel depressed — but how it is affecting your work, your sleep, your ability to show up for the people and responsibilities in your life. That specificity matters clinically.
• Write down your questions in advance. Appointments move quickly. Having your questions written down means you get answers to what actually matters to you.

During the Appointment

Ask these questions directly:

1. Why this specific medication or strategy? You deserve to understand the clinical reasoning, not just receive a prescription.
2. What does an adequate trial look like? Get clarity on the dose target and the timeframe before you can reasonably assess response.
3. What is the next step if this does not work? A provider with a structured approach to TRD should be able to articulate the pathway ahead, not just take it one step at a time without a plan.
4. Has my diagnosis been re-examined recently? If you have been in treatment for years without meaningful improvement, this is a legitimate and important clinical question.
5. Are there options — augmentation, interventional treatments — that we have not yet discussed? It is appropriate to ask.

If You Feel Unheard

This is a real issue in outpatient psychiatry. High-volume practices and short appointment slots do not always allow for the depth of conversation that complex presentations require. If you have consistently left appointments with more confusion than clarity, that is not a reflection of your difficulty as a patient. It is a reflection of a system that was not designed to slow down for complexity. Seeking a second opinion or a more structured evaluation is a reasonable, clinically appropriate step — not a betrayal of your current provider.

For patients across California navigating this — including working professionals, healthcare workers, educators, veterans, and first responders — telehealth-based psychiatric care has made it significantly more practical to access that second layer of evaluation without disrupting a full work schedule.

Frequently Asked Questions

How many antidepressants do I need to try before I qualify as treatment-resistant?

The standard clinical threshold is two adequate trials — meaning two different antidepressants at therapeutic doses for a sufficient duration, typically at least six to eight weeks each. If either trial was stopped early due to side effects before reaching an adequate dose or duration, it may not qualify as a true failed trial, which is why a detailed medication history review matters.

Can treatment-resistant depression be fully treated?

Many patients with TRD do achieve meaningful response and remission — sometimes with augmentation strategies, sometimes with interventional treatments like TMS or esketamine, and sometimes with a revised diagnosis that unlocks a more targeted treatment approach. According to the Mayo Clinic, treatment-resistant depression is challenging but treatable, and most people do find a combination of treatments that provides significant relief. Outcomes vary by individual, and no ethical provider will promise a specific result — but the evidence base for next-step options is real and substantive.

Is esketamine covered by insurance?

Coverage for esketamine (Spravato) varies by insurance plan and requires prior authorization in most cases, typically with documentation of prior failed antidepressant trials. Insurance-based access to psychiatric care — including navigating these coverage questions — is something a knowledgeable psychiatric provider can help you work through.

Should I consider TMS before esketamine, or the other way around?

There is no universal answer. The decision depends on your specific clinical history, the severity of your current episode, your insurance coverage, your logistical access to each treatment, and your individual risk profile. This is exactly the kind of decision that requires a structured evaluation rather than a general recommendation. Both TMS and esketamine are legitimate first-choice interventional options when standard pharmacotherapy has failed — the sequencing depends on your picture specifically.

Moving Forward With Structure, Not Frustration

Treatment-resistant depression is a demanding clinical challenge — but it is one with a genuine, evidence-based roadmap. The pathway forward involves a careful re-examination of the diagnostic picture, a structured review of what has and has not been tried, and a deliberate progression through augmentation and interventional options that are matched to your specific clinical profile.

What that requires from a provider is time, clinical specificity, and a willingness to slow down and get it right. What it requires from you is the willingness to keep asking the right questions and to seek the level of care that your situation actually warrants.

If you are in California and navigating this without a clear plan, D&Y Integrated Psychiatry offers structured, insurance-based outpatient psychiatric care for adults — including a thorough initial evaluation that is designed to give you clarity about your diagnosis, your treatment history, and what the evidence supports as a next step. The practice’s background includes specialized experience in TMS-focused treatment and a clinical approach built around exactly the kind of complex presentations this post addresses.

Book an Appointment to find out whether a structured psychiatric evaluation at D&Y is the right next step for you. No pressure. Just a direct conversation about where you are clinically and whether this practice is a good fit to help you move forward.